StockData

Inhibrx Biosciences vs SAB Biotherapeutics

INBX and SABS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INBX and SABS compare

Inhibrx Biosciences is the larger company, worth 4.1 times as much as SAB Biotherapeutics ($1.1B against $268M).

SAB Biotherapeutics scores higher on the StockData Score (4 against 1 for Inhibrx Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINBXSABS
Size and price
Market cap$1.1B$268M
Share price$74.18$2.95
Change, 1 year−6.3%−9.0%
Change, 5 years93.5%−97.2%
Beta (5Y)2.161.07
Employees11086
StockData Score
Total score14 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score12 (better)
Dividend score00
Valuation
P/B–1.2×
FCF yield−12.2%–
Growth
Revenue growth, 5Y average−36.8%–
Profitability
Return on equity–−11.3%
Return on invested capital–−95.8%
Financial health
Interest coverage−5.9× (better)−310.3×
Current ratio7.589.22 (better)
Altman Z-score−1.025.47 (better)
Piotroski F-score14 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions97.4%75.2%
Held by insiders35.4%30.2%
Insider net buying, 12 months$6.1M–
Superinvestors holding1–
Short interest, % of float35.7%7.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.